Correction: A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer’s disease with lecanemab, an anti-Aβ protofibril antibody

Overview of attention for article published in Alzheimer's Research & Therapy, May 2022

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (83rd percentile)

Mentioned by

news: 1 news outlet

twitter: 1 X user

Citations

dimensions_citation: 4 Dimensions

Readers on

mendeley: 28 Mendeley

Summary News X Dimensions citations

So far, Altmetric has seen 1 X post from an account with 467 followers.

New article: Correction to: A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer's disease with lecanemab, an anti-Aβ protofibril antibody https://t.co/GUD4thbkCR #alzheimers #neurology https://t.co/2hnpe7VxcE

Reply Repost Favourite

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity.